Traws Pharma (TRAW) AI Stock Analysis

• Market Cap: $15.50M
• Dividend Yield: N/A
• Average Volume (3M): 206.36K
• Price to Earnings (P/E): <0.1
• Beta (1Y): 0.52
• Revenue Growth: 1159.29%
• EPS Growth: N/A
• Country: US
• Employees: 6
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.34
• Shares Outstanding: 7,990,867
• 10 Day Avg. Volume: 403,079
• 30 Day Avg. Volume: 206,356
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.44
• Price to Sales (P/S): 61.01
• P/FCF Ratio: -0.46
• Enterprise Value/Market Cap: -0.31
• Enterprise Value/Revenue: -1.75
• Enterprise Value/Gross Profit: -1.75
• Enterprise Value/Ebitda: 0.45
• 1Y Price Target: $7.25
• Price Target Upside: 273.71% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 56 Neutral
• Price Target: $2.00 ▲(3.09% Upside)

The score is held back primarily by weak financial performance (widening losses, rising cash burn, and negative equity), which elevates funding risk. Offsetting this are strong technical momentum (price above major moving averages with positive MACD) and multiple positive corporate catalysts tied to COVID and influenza pipeline progress, while valuation metrics are not supportive/meaningful given the loss-making profile.

Positive Factors

Pipeline clinical progress

Completing Phase 2 enrollment with favorable interim safety and efficacy signals materially raises the likelihood of clear next-step data readouts and regulatory discussions. Durable clinical momentum strengthens the company’s positioning versus ritonavir-based options and supports long-term commercial potential.

Regulatory pathway and strategic stockpile relevance

An IND filing that positions a compound for BARDA consideration creates a structural commercial channel beyond retail sales. Inclusion in strategic stockpiles or government programs can produce stable, large-volume demand and de-risks revenue concentration for a clinical-stage antiviral developer over multiple years.

No debt on balance sheet

A debt-free capital structure lowers fixed financial obligations and interest expense, preserving operational flexibility while advancing costly clinical programs. For a pre-commercial biotech, absence of leverage improves resilience to revenue variability and reduces bankruptcy/default tail risk.

Negative Factors

Widening losses and accelerating cash burn

Rapidly increasing net losses and operating cash outflows materially shorten runway and raise near-term external funding needs. This structural cash consumption elevates dilution and execution risk, potentially forcing financing or program prioritization that could delay or curtail planned clinical milestones.

Negative shareholders' equity

Negative equity reflects accumulated operating losses that weaken balance-sheet cushioning and limit borrowing capacity. This persistent deficit diminishes counterparty confidence and can complicate partnership, licensing, or supplier negotiations, increasing structural funding and operational fragility.

Minimal and immaterial revenue base

With negligible recurring revenue, the business remains fully dependent on R&D milestones and external capital. Lack of diversified commercial income means trial outcomes and financing cycles will determine sustainability, increasing long-term execution risk absent successful product approvals or durable partnerships.

Traws Pharma Business Overview & Revenue Model

Company Description

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

How the Company Makes Money

Traws Pharma generates revenue primarily through the sale of its pharmaceutical products and therapies that have gained regulatory approval. The company also engages in licensing agreements, where it grants other pharmaceutical firms access to its proprietary technologies and compounds in exchange for upfront payments, milestone fees, and royalties on sales. Additionally, Traws Pharma may receive funding from research grants and collaborations with academic institutions or other industry players. Strategic partnerships with larger pharmaceutical companies also contribute to its earnings, facilitating the co-development and co-promotion of new therapies.

Traws Pharma Financial Statement Overview

Summary

Financial statements reflect a pre-commercial biotech with immaterial and largely flat revenue, materially widening losses (net loss ~$54.7M in 2024 vs. ~$18.9M in 2023), and worsening operating cash burn (~-$29.8M in 2024 vs. ~-$17.9M in 2023). No debt is a positive, but the move to negative equity in 2024 increases funding risk.

Income Statement

Revenue is very small and largely flat in recent years (~$226K annually), despite a sharp reported growth rate in 2024 that still leaves the revenue base immaterial. Gross margin is high (typical of biotech), but the cost structure is far too large for the current revenue level: operating losses widened materially in 2024 (net loss ~$54.7M vs. ~$18.9M in 2023), driving extremely negative profitability. Overall, the income statement reflects a pre-commercial business with accelerating losses and limited near-term earnings visibility.

Balance Sheet

The company reports no debt, which reduces financial risk and interest burden. However, equity turned negative in 2024 (stockholders’ equity about -$31.6M vs. +$10.7M in 2023), signaling substantial accumulated losses and weakening balance-sheet cushioning. Total assets are modest (~$25.0M in 2024) and down versus earlier years, which can constrain flexibility if cash needs persist.

Cash Flow

Cash burn remains significant and is moving in the wrong direction: operating cash flow was about -$29.8M in 2024 versus -$17.9M in 2023, with free cash flow similarly negative. Free cash flow is consistently negative across the period, indicating ongoing reliance on external funding. While cash flow tracks net losses closely (losses are being realized in cash), the key takeaway is sustained and increasing cash consumption.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.79M	226.00K	226.00K	226.00K	226.00K	231.00K
Gross Profit	2.79M	214.00K	226.00K	226.00K	226.00K	231.00K
EBITDA	-10.97M	-166.51M	-20.28M	-19.61M	-16.48M	-24.98M
Net Income	-9.10M	-54.67M	-18.95M	-18.96M	-16.16M	-25.16M
Balance Sheet
Total Assets	15.62M	24.96M	22.68M	39.37M	55.48M	19.99M
Cash, Cash Equivalents and Short-Term Investments	13.08M	21.34M	20.82M	38.76M	55.07M	19.02M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	7.36M	56.59M	12.01M	11.06M	9.36M	13.81M
Stockholders Equity	8.26M	-31.63M	10.67M	28.31M	46.12M	6.17M
Cash Flow
Free Cash Flow	-10.02M	-29.79M	-17.95M	-16.29M	-19.49M	-23.09M
Operating Cash Flow	-10.02M	-29.79M	-17.93M	-16.29M	-19.49M	-23.07M
Investing Cash Flow	0.00	-3.65M	-14.00K	0.00	0.00	-15.00K
Financing Cash Flow	23.07M	33.98M	0.00	0.00	55.56M	19.36M

Traws Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.94
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRAW, the sentiment is Negative. The current price of 1.94 is below the 20-day moving average (MA) of 2.04, below the 50-day MA of 1.94, and above the 200-day MA of 1.82, indicating a neutral trend. The MACD of 0.11 indicates Positive momentum. The RSI at 47.89 is Neutral, neither overbought nor oversold. The STOCH value of 10.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TRAW.

Traws Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TRAW	56 Neutral	$15.50M	0.08	7432.32%	―	1159.29%	―
LSTA	52 Neutral	$41.55M	-2.22	-71.45%	―	―	15.32%
APLM	52 Neutral	$21.49M	-0.69	-380.13%	―	―	54.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Traws Pharma Corporate Events

Traws Pharma Completes Phase 2 Enrollment for COVID Candidate

On January 26, 2026, Traws Pharma reported it had completed enrollment in a 90-patient open-label Phase 2 study of its oral COVID-19 candidate ratutrelvir, comparing it with PAXLOVID in PAXLOVID-eligible patients and in a separate cohort of patients ineligible for ritonavir-based regimens, a group often at higher risk of severe disease. Interim clinical observations highlighted fewer adverse events, absence of viral rebound to date, faster and sustained symptom resolution, and favorable tolerability for ratutrelvir, reinforcing its potential to address a sizeable market segment that cannot use ritonavir and to offer a differentiated profile that may also have implications for reducing post-acute sequelae of SARS-CoV-2 infection. The company also advanced its influenza franchise, outlining plans to pursue an additional indication for tivoxavir marboxil as a once-monthly oral prophylactic for seasonal influenza, supported by earlier Phase 1 data showing prolonged therapeutic blood levels and a new compressed tablet formulation expected to provide 28 days of protection, with a human influenza prophylaxis challenge study already scheduled for June 2026, positioning Traws for multiple upcoming clinical and value inflection points in the multi-billion-dollar antiviral market for COVID-19 and flu.

The most recent analyst rating on (TRAW) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.

Traws Pharma advances flu and COVID-19 antiviral pipeline

On January 13, 2026, Traws Pharma filed a U.S. Investigational New Drug application with the FDA for tivoxavir marboxil (TXM), a potential best-in-class, single-dose oral CAP-dependent endonuclease inhibitor for the treatment of seasonal and avian influenza, a move that represents the final step toward formal consideration by BARDA for inclusion in the U.S. strategic national stockpile. In a separate update from an ongoing randomized Phase 2 trial in mild-to-moderate COVID-19, the company reported interim data in 50 patients showing that ratutrelvir, its ritonavir-free oral 3CL protease inhibitor, delivered faster sustained symptom resolution than PAXLOVID, no observed viral or symptom rebound events, fewer adverse effects and favorable tolerability, including in PAXLOVID-ineligible patients at higher risk of severe disease, reinforcing Traws’ bid to position ratutrelvir as a next-generation COVID-19 therapy and to expand its role in both acute treatment and potential long-COVID prevention strategies.

The most recent analyst rating on (TRAW) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.

Traws Pharma Reports Positive Phase 2 Trial Results

Traws Pharma announced positive interim results from a Phase 2 trial of ratutrelvir, a ritonavir-free oral COVID-19 treatment, on December 17, 2025. The data highlighted a favorable safety profile, no viral rebounds, and potential benefits for patients ineligible for Paxlovid due to contraindications, as well as its potential role in Long COVID prevention. With a differentiated clinical profile, this investigational treatment positions Traws Pharma as a key contender in the multi-billion-dollar COVID-19 therapeutic market.

The most recent analyst rating on (TRAW) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.

Traws Pharma Approves Executive Stock Options

On December 12, 2025, Traws Pharma‘s Compensation Committee approved stock options and restricted stock units for its executive officers. This decision, under the 2021 Incentive Compensation Plan, aims to incentivize key leaders, potentially impacting the company’s operational focus and market positioning.

The most recent analyst rating on (TRAW) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.

Traws Pharma Holds Virtual Annual Meeting 2025

On November 21, 2025, Traws Pharma held its Annual Meeting virtually, with 48% of its outstanding shares represented. During the meeting, stockholders elected seven directors, approved amendments to the 2021 Incentive Compensation Plan, and ratified KPMG LLP as the independent auditor for 2025. Additionally, it was decided that advisory votes on executive compensation will occur every two years, with the next vote scheduled for the 2027 Annual Meeting.

Traws Pharma Reports Q3 2025 Financial Results

On November 13, 2025, Traws Pharma announced its financial results for the quarter ending September 30, 2025, highlighting significant cost reductions and the acquisition of intellectual property assets. The company is advancing its Phase 2 studies for ratutrelvir, a potential COVID-19 therapy, and tivoxavir marboxil for bird flu and seasonal flu, both representing substantial market opportunities. The company also reported management updates and a decrease in net loss compared to the previous year, indicating a strategic shift towards antiviral programs and partnerships for legacy oncology assets.

The most recent analyst rating on (TRAW) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Traws Pharma stock, see the TRAW Stock Forecast page.